Centers for Disease Control and Protection (CDC) Cites Risk of Zika Virus Through Sexual Transmission, Recommends Female Condoms to Help Prevent Infection

CHICAGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- The Female Health Company (NASDAQ:FHCO) (FHC) today commented on updated guidance issued by the Centers for Disease Control and Protection (CDC) to prevent the transmission of the Zika virus. Last week, the CDC recommended the use of condoms (female or male condoms) by all pregnant women with sex partners (male or female) who live in or traveled to an area with Zika. The CDC also said that all other couples in which a partner (male or female) has been in an area with Zika can also reduce the risk of sexual transmission by using condoms. 

“The CDC’s expanded guidance is based on recently reported cases in Florida of female-to-male sexual transmission of the Zika virus,” said O.B. Parrish, Chairman and Chief Executive Officer of The Female Health Company. “The CDC previously confirmed a link between Zika virus and babies born with microcephaly, a serious birth defect, as well as an increase in Guillain-Barre syndrome among adults.” 

“Zika is not only a cause for concern for both men and women, but a serious health risk to unborn children of pregnant women. Accordingly, we have expanded our efforts to work closely with the Departments of Health of cities and municipalities across the U.S., as well leading health organizations throughout the world to help prevent the spread of Zika. FHC will continue to provide not only access to, but also education regarding the FC2 Female Condom. This will ensure that communities have access to scientifically proven and efficacious methods to keep the community safe and healthy,” said Lisa Levin, Director of Marketing for FHC.

FHC’s FC2 Female Condom is the only product of its kind approved by the U.S. Food and Drug Administration (FDA) and cleared by the World Health Organization (WHO) and under a women’s control. FC2 provides women a non-hormonal option for their contraception and disease prevention needs. The product’s efficacy is comparable to male condoms in protecting against unplanned pregnancy as well and sexually transmitted infections (STIs), including Zika. The Company has an expanded mission to assist in protecting women of all ages - pregnant or not - from being infected by STI’s, including the Zika virus.  

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of the FC2 manufacturing process and design. The FC2 Female Condom® is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, the Zika virus and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. 

For more information about the Female Health Company visit the Company's website at and If you would like to be added to the Company's e-mail alert list, please send an e-mail to

William R. Gargiulo, Jr. 231.526.1244
Michele Greco, CFO 312.595.9123

Primary Logo

Female Health Company